Publications by authors named "Howard Scher"

Claim this Profile
A
Anti-tumour effects of perioperative ketamine in lung cancer: a non-randomised, exploratory biomarker study.
Stephanie N Shishido, Anya Shah, Jeremy Mason, Joseph R Scarpa, David Amar, Gregory W Fischer, Howard Scher

Br J Anaesth· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.
Wenjing Su, Hyun Ho Han, Yan Wang, Boyu Zhang, Bing Zhou, Howard I Scher

Cancer Cell· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating Drug Development in Hormone-Naïve Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
Deaglan McHugh, Matthew Dallos, Min Yuen Teo, Sean M McBride, Anuradha Gopalan, Howard I Scher

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two Decades of Disease Evolution and Biomarker-Guided Clinical Decision Making in Metastatic Prostate Cancer.
Tatiana Erazo, Enrico Moiso, Omer Aras, Howard I Scher

Int J Mol Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
Karen A Autio, Christos E Kyriakopoulos, Paul Palyca, Han Xiao, Hamid Emamekhoo, Howard I Scher

Invest New Drugs· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Ultra-Hypofractionated Stereotactic Radiation After Radical Prostatectomy Cut Time on Treatment or Are the Data Not Sharp Enough?
Sean M McBride, Howard I Scher

JAMA Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer.
Marjorie L Roskes, Alexander Martinez-Fundichely, Sandra Cohen, Metin Balaban, Chen Khuan Wong, Howard I Scher

medRxiv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.
Karen A Autio, Deaglan J McHugh, Dana E Rathkopf, Han Xiao, Swathi Merugu, Howard I Scher

J Immunother Precis Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer.
Fourat Ridouani, H Alberto Vargas, Daniel J Holzwanger, Heiko Schöder, Emily Waters, Howard I Scher

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons.
Robert L Grossman, Jake Vinson, Elizabeth Bain, Karl Bisselou, Sanchi Chandan, Howard Scher

Clin Transl Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer.
Casey R Ager, Aleksandar Obradovic, Patrick McCann, Matthew Chaimowitz, Alexander L E Wang, Howard I Scher

medRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Karim Fizazi, Howard I Scher

Eur Urol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards Preanalytical Best Practices for Liquid Biopsy Studies: A BLOODPAC Landscape Analysis.
Christina M Lockwood, Jason D Merker, Elizabeth Bain, Caroline Compton, Robert L Grossman, Howard Scher

Clin Pharmacol Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated real-world data integration improves cancer outcome prediction.
Justin Jee, Christopher Fong, Karl Pichotta, Thinh Ngoc Tran, Anisha Luthra, Howard Scher

Nature· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, Nivedita Chowdhury, Aditya Pratapa, Howard I Scher

Clin Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two decades of advances in clinical oncology - lessons learned and future directions.
Susana Banerjee, Christopher M Booth, Eduardo Bruera, Markus W Büchler, Alexander Drilon, Howard I Scher

Nat Rev Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
Si-Yang Liu, Tatiana Erazo, Justin Jee, Andrea Arfe, Avantika Gupta, Howard I Scher

Eur J Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
Andrew T Lenis, Vignesh Ravichandran, Samantha Brown, Syed M Alam, Andrew Katims, Howard I Scher

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
Samir Zaidi, Jooyoung Park, Joseph M Chan, Martine P Roudier, Jimmy L Zhao, Howard I Scher

Proc Natl Acad Sci U S A· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies.
Samir Zaidi, Jooyoung Park, Joseph M Chan, Martine P Roudier, Jimmy L Zhao, Howard I Scher

bioRxiv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.
E David Crawford, Alan H Bryce, Maha H Hussain, Neeraj Agarwal, Himisha Beltran, Howard I Scher

JU Open Plus· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.
Alan H Bryce, E David Crawford, Neeraj Agarwal, Maha H Hussain, Himisha Beltran, Howard I Scher

JU Open Plus· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy.
Charlotte S Walmsley, Philip Jonsson, Michael L Cheng, Sean McBride, Christopher Kaeser, Howard I Scher

NPJ Precis Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
Daniel Vargas P de Almeida, Justine M Anderson, Daniel C Danila, Michael J Morris, Susan F Slovin, Howard I Scher

J Immunother Precis Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods.
Emre Uygur, Ceren Sezgin, Yasemin Parlak, Kadriye Busra Karatay, Bilal Arikbasi, Howard Scher

Res Sq· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis